APGE
Apogee Therapeutics, Inc.
Price Chart
Latest Quote
$84.19
+5.48 (+6.96%)
Current Price
| Previous Close | $78.71 |
| Open | $78.71 |
| Day High | $85.18 |
| Day Low | $78.71 |
| Volume | 1,065,930 |
Stock Information
| Shares Outstanding | 61.90M |
| Total Debt | $8.05M |
| Cash Equivalents | $1.06B |
| Net Income | $-274.62M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $6.55B |
| EPS (TTM) | $-4.33 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.46B |
| Income | $-274.62M |
| Book/sh | $16.87 |
| Cash/sh | $17.12 |
| Employees | 261 |
Financial Ratios
| Quick Ratio | 32.38 |
| Current Ratio | 32.59 |
| Debt/Eq | 0.64 |
Returns & Margins
| ROA | -19.00% |
| ROE | -28.47% |
Ownership
| Insider Ownership | 9.68% |
| Institutional Ownership | 131.10% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -16.97 |
| P/B | 5.15 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $118.35 |
Technical Indicators
| SMA20 | $82.10 |
| SMA50 | $83.95 |
| SMA200 | $67.16 |
| RSI | 57.41 |
| ATR | 5.0450 |
| Shares Float | 57.83M |
| Short Float | 19.59% |
| Short Ratio | 14.63 |
| Volatility | 0.62 |
| Rel Volume | 1.28 |
Performance History
| Week | +5.82% |
| Month | +2.82% |
| Quarter | +18.99% |
| 6 Months | +16.59% |
| YTD | +14.70% |
| Year | +138.14% |
| 10 Years | +309.42% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $86.92 | 1,307,800 |
| 2026-06-04 | $90.90 | 1,471,200 |
| 2026-06-03 | $84.19 | 1,129,100 |
| 2026-06-02 | $78.71 | 1,113,600 |
| 2026-06-01 | $79.30 | 806,700 |
| 2026-05-29 | $82.14 | 1,416,800 |
| 2026-05-28 | $77.82 | 1,244,300 |
| 2026-05-27 | $77.75 | 4,032,200 |
| 2026-05-26 | $82.81 | 443,700 |
| 2026-05-22 | $81.16 | 338,400 |
| 2026-05-21 | $82.43 | 369,900 |
| 2026-05-20 | $81.39 | 766,800 |
| 2026-05-19 | $78.27 | 976,500 |
| 2026-05-18 | $78.75 | 748,100 |
| 2026-05-15 | $81.14 | 714,800 |
| 2026-05-14 | $83.91 | 631,400 |
| 2026-05-13 | $83.94 | 745,800 |
| 2026-05-12 | $82.93 | 497,100 |
| 2026-05-11 | $84.60 | 983,900 |
| 2026-05-08 | $83.03 | 768,700 |
| 2026-05-07 | $81.81 | 376,700 |
| 2026-05-06 | $84.54 | 413,700 |
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
đ° Latest News
Apogee (APGE) Secures Up to $1.3B in Non-Dilutive Financing from Blackstone to Advance Zumilokibart
Insider Monkey âĸ 2026-06-05T12:55:35Z
Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing
MarketBeat âĸ 2026-06-04T09:04:28Z
Assessing Apogee Therapeutics (APGE) Valuation After Positive Phase 2 APEX Results For Zumilokibart
Simply Wall St. âĸ 2026-06-01T05:04:58Z
Apogee Therapeutics lines up $1.3B strategic financing for zumilokibart program
Proactive âĸ 2026-05-28T18:43:00Z
Why Apogee Slipped On Its Dupixent-Rivaling Eczema Results
Investor's Business Daily âĸ 2026-05-27T20:05:25Z
Blackstone Backs Apogee With Up To $1.3 Billion
GuruFocus.com âĸ 2026-05-27T18:33:27ZApogee secures up to $1.3 billion from Blackstone to advance eczema drug
Reuters âĸ 2026-05-27T12:58:48ZApogee Therapeutics Shares Surge Following $1.3 Billion Blackstone Financing Partnership (APOG)
InvestorsHub âĸ 2026-05-27T12:06:43Z
Apogee Therapeutics, Blackstone Life Sciences Enter Financing Collaboration of Up to $1.3 Billion
MT Newswires âĸ 2026-05-27T11:10:32ZApogee Therapeutics Inc. (APGE): Primary Challenger to Established Blockbusters
Insider Monkey âĸ 2026-04-27T14:05:16Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $285,595,000 | $216,870,000 | $93,003,000 | $30,727,000 |
| Net Non Operating Interest Income Expense | $30,030,000 | $34,742,000 | $9,018,000 | $-9,058,000 |
| Operating Expense | $285,595,000 | $216,870,000 | $93,003,000 | $30,727,000 |
| General And Administrative Expense | $69,753,000 | $49,005,000 | $24,579,000 | $2,941,000 |
| Interest Expense | - | - | $0 | $9,150,000 |
| Interest Expense Non Operating | - | - | $0 | $9,150,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-255,843,000 | $-182,146,000 | $-83,985,000 | $-39,785,000 |
| Net Interest Income | $30,030,000 | $34,742,000 | $9,018,000 | $-9,058,000 |
| Interest Income | $30,030,000 | $34,742,000 | $9,018,000 | $92,000 |
| Normalized Income | $-255,843,000 | $-182,146,000 | $-83,985,000 | $-39,785,000 |
| Net Income From Continuing And Discontinued Operation | $-255,843,000 | $-182,146,000 | $-83,985,000 | $-39,785,000 |
| Total Operating Income As Reported | $-285,595,000 | $-216,870,000 | $-93,003,000 | $-30,727,000 |
| Net Income Common Stockholders | $-255,843,000 | $-182,146,000 | $-83,985,000 | $-39,785,000 |
| Net Income | $-255,843,000 | $-182,146,000 | $-83,985,000 | $-39,785,000 |
| Net Income Including Noncontrolling Interests | $-255,843,000 | $-182,146,000 | $-83,985,000 | $-39,785,000 |
| Net Income Continuous Operations | $-255,843,000 | $-182,146,000 | $-83,985,000 | $-39,785,000 |
| Pretax Income | $-255,565,000 | $-182,128,000 | $-83,985,000 | $-39,785,000 |
| Interest Income Non Operating | $30,030,000 | $34,742,000 | $9,018,000 | $92,000 |
| Operating Income | $-285,595,000 | $-216,870,000 | $-93,003,000 | $-30,727,000 |
| Depreciation Amortization Depletion Income Statement | $1,130,000 | $0 | - | - |
| Depreciation And Amortization In Income Statement | $1,130,000 | $0 | - | - |
| Depreciation Income Statement | $1,130,000 | $0 | - | - |
| Per Share | ||||
| Diluted EPS | - | $-3.30 | $-3.36 | $-1.46 |
| Basic EPS | - | $-3.30 | $-3.36 | $-1.46 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-284,177,000 | $-216,681,000 | $-93,003,000 | $-30,635,000 |
| Reconciled Depreciation | $1,418,000 | $189,000 | $0 | - |
| EBITDA (Bullshit earnings) | $-284,177,000 | $-216,681,000 | $-93,003,000 | $-30,635,000 |
| EBIT | $-285,595,000 | $-216,870,000 | $-93,003,000 | $-30,635,000 |
| Diluted NI Availto Com Stockholders | $-255,843,000 | $-182,146,000 | $-83,985,000 | $-39,785,000 |
| Tax Provision | $278,000 | $18,000 | $0 | - |
| Research And Development | $214,712,000 | $167,865,000 | $68,424,000 | $27,786,000 |
| Selling General And Administration | $69,753,000 | $49,005,000 | $24,579,000 | $2,941,000 |
| Other Gand A | $19,117,000 | $18,702,000 | $24,579,000 | $1,299,000 |
| Salaries And Wages | $50,636,000 | $30,303,000 | $12,577,000 | $1,642,000 |
| Diluted Average Shares | - | $55,193,971 | $25,005,774 | $27,246,823 |
| Basic Average Shares | - | $55,193,971 | $25,005,774 | $27,246,823 |
Fetched: 2026-06-03
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $903,883,000 | $716,794,000 | $379,913,000 | $0 |
| Total Assets | $937,134,000 | $753,951,000 | $401,404,000 | $152,055,000 |
| Total Non Current Assets | $195,776,000 | $224,238,000 | $2,995,000 | $0 |
| Other Non Current Assets | $8,671,000 | $498,000 | $401,000 | - |
| Investmentin Financial Assets | $172,730,000 | $210,416,000 | $0 | - |
| Current Assets | $741,358,000 | $529,713,000 | $398,409,000 | $152,055,000 |
| Other Current Assets | $605,000 | $1,742,000 | $1,214,000 | $57,000 |
| Prepaid Assets | $4,600,000 | $2,621,000 | $1,736,000 | $108,000 |
| Receivables | $5,961,000 | $4,697,000 | $1,214,000 | - |
| Accrued Interest Receivable | $5,961,000 | $4,697,000 | $1,214,000 | - |
| Cash Cash Equivalents And Short Term Investments | $730,192,000 | $520,653,000 | $395,459,000 | $151,890,000 |
| Cash And Cash Equivalents | $131,549,000 | $141,789,000 | $118,316,000 | $151,890,000 |
| Cash Financial | - | - | - | $151,890,000 |
| Debt | ||||
| Total Debt | $8,849,000 | $11,831,000 | $2,034,000 | $0 |
| Long Term Debt And Capital Lease Obligation | $5,345,000 | $8,597,000 | $933,000 | $0 |
| Current Debt And Capital Lease Obligation | $3,504,000 | $3,234,000 | $1,101,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $33,251,000 | $37,157,000 | $21,491,000 | $9,980,000 |
| Total Non Current Liabilities Net Minority Interest | $5,345,000 | $8,597,000 | $933,000 | $0 |
| Current Liabilities | $27,906,000 | $28,560,000 | $20,558,000 | $9,980,000 |
| Payables And Accrued Expenses | $20,744,000 | $23,431,000 | $19,290,000 | $9,465,000 |
| Payables | $1,221,000 | $1,071,000 | $2,143,000 | $418,000 |
| Accounts Payable | $1,221,000 | $1,071,000 | $2,143,000 | $418,000 |
| Equity | ||||
| Common Stock Equity | $903,883,000 | $716,794,000 | $379,913,000 | $0 |
| Total Equity Gross Minority Interest | $903,883,000 | $716,794,000 | $379,913,000 | $142,075,000 |
| Stockholders Equity | $903,883,000 | $716,794,000 | $379,913,000 | $0 |
| Gains Losses Not Affecting Retained Earnings | $1,080,000 | $915,000 | $329,000 | $0 |
| Other Equity Adjustments | $1,080,000 | $915,000 | $329,000 | - |
| Retained Earnings | $-561,759,000 | $-305,916,000 | $-123,770,000 | $-39,785,000 |
| Other | ||||
| Ordinary Shares Number | $68,401,349 | $59,478,725 | $48,519,326 | $48,017,621 |
| Share Issued | $68,401,349 | $59,478,725 | $48,519,326 | $48,017,621 |
| Tangible Book Value | $903,883,000 | $716,794,000 | $379,913,000 | $0 |
| Invested Capital | $903,883,000 | $716,794,000 | $379,913,000 | $0 |
| Working Capital | $713,452,000 | $501,153,000 | $377,851,000 | $142,075,000 |
| Capital Lease Obligations | $8,849,000 | $11,831,000 | $2,034,000 | $0 |
| Total Capitalization | $903,883,000 | $716,794,000 | $379,913,000 | $142,075,000 |
| Additional Paid In Capital | $1,464,561,000 | $1,021,794,000 | $503,354,000 | $0 |
| Capital Stock | $1,000 | $1,000 | $0 | $0 |
| Common Stock | $1,000 | $1,000 | $0 | $0 |
| Long Term Capital Lease Obligation | $5,345,000 | $8,597,000 | $933,000 | $0 |
| Current Capital Lease Obligation | $3,504,000 | $3,234,000 | $1,101,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,658,000 | $1,895,000 | $167,000 | $515,000 |
| Current Accrued Expenses | $19,523,000 | $22,360,000 | $17,147,000 | $9,047,000 |
| Investments And Advances | $172,730,000 | $210,416,000 | $0 | - |
| Available For Sale Securities | $172,730,000 | $210,416,000 | - | - |
| Net PPE | $14,375,000 | $13,324,000 | $2,594,000 | $0 |
| Accumulated Depreciation | $-1,608,000 | $-189,000 | $0 | - |
| Gross PPE | $15,983,000 | $13,513,000 | $2,594,000 | $0 |
| Leases | $3,075,000 | $863,000 | $0 | - |
| Other Properties | $10,156,000 | $12,650,000 | $2,594,000 | - |
| Machinery Furniture Equipment | $2,752,000 | $0 | - | - |
| Properties | $0 | $0 | $0 | - |
| Other Short Term Investments | $598,643,000 | $378,864,000 | $277,143,000 | $0 |
| Preferred Stock | - | $0 | $0 | $0 |
| Total Partnership Capital | - | $-305,001,000 | $-123,441,000 | $142,075,000 |
| Limited Partnership Capital | - | $0 | $0 | $181,860,000 |
| General Partnership Capital | - | - | - | $2,142,000 |
Fetched: 2026-06-03
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-232,597,000 | $-172,326,000 | $-74,928,000 | $-16,427,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-227,450,000 | $-171,174,000 | $-74,761,000 | $-16,427,000 |
| Cash Flow From Continuing Operating Activities | $-227,450,000 | $-171,174,000 | $-74,761,000 | $-16,427,000 |
| Investing Activities | ||||
| Capital Expenditure | $-5,147,000 | $-1,152,000 | $-167,000 | - |
| Investing Cash Flow | $-179,574,000 | $-300,462,000 | $-273,910,000 | $0 |
| Cash Flow From Continuing Investing Activities | $-179,574,000 | $-300,462,000 | $-273,910,000 | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $389,634,000 | $493,483,000 | $315,391,000 | $168,317,000 |
| Financing Cash Flow | $396,490,000 | $495,109,000 | $315,391,000 | $168,317,000 |
| Cash Flow From Continuing Financing Activities | $396,490,000 | $495,109,000 | $315,391,000 | $168,317,000 |
| Net Common Stock Issuance | $389,634,000 | $493,483,000 | $315,391,000 | $0 |
| Common Stock Issuance | $389,634,000 | $493,483,000 | $315,391,000 | $0 |
| Net Preferred Stock Issuance | - | - | $0 | $168,317,000 |
| Preferred Stock Issuance | - | - | $0 | $168,317,000 |
| Other | ||||
| End Cash Position | $131,549,000 | $142,083,000 | $118,610,000 | $151,890,000 |
| Beginning Cash Position | $142,083,000 | $118,610,000 | $151,890,000 | $0 |
| Changes In Cash | $-10,534,000 | $23,473,000 | $-33,280,000 | $151,890,000 |
| Proceeds From Stock Option Exercised | $6,856,000 | $1,626,000 | $0 | - |
| Net Investment Purchase And Sale | $-174,427,000 | $-299,310,000 | $-273,743,000 | $0 |
| Sale Of Investment | $467,873,000 | $350,140,000 | $30,000,000 | $0 |
| Purchase Of Investment | $-642,300,000 | $-649,450,000 | $-303,743,000 | $0 |
| Net PPE Purchase And Sale | $-5,147,000 | $-1,152,000 | $-167,000 | $0 |
| Purchase Of PPE | $-5,147,000 | $-1,152,000 | $-167,000 | $0 |
| Change In Working Capital | $-15,478,000 | $-2,002,000 | $6,105,000 | $9,815,000 |
| Change In Other Current Liabilities | $-3,981,000 | $-1,045,000 | $-270,000 | $0 |
| Change In Other Current Assets | $-8,467,000 | $-97,000 | $-107,000 | $0 |
| Change In Payables And Accrued Expense | $-924,000 | $5,220,000 | $9,267,000 | $9,980,000 |
| Change In Accrued Expense | $-1,074,000 | $6,292,000 | $7,654,000 | $9,562,000 |
| Change In Payable | $150,000 | $-1,072,000 | $1,613,000 | $418,000 |
| Change In Account Payable | $150,000 | $-1,072,000 | $1,613,000 | $418,000 |
| Change In Prepaid Assets | $-2,106,000 | $-6,080,000 | $-2,785,000 | $-165,000 |
| Other Non Cash Items | $3,677,000 | $1,694,000 | $87,000 | $11,401,000 |
| Stock Based Compensation | $46,277,000 | $23,332,000 | $6,103,000 | $2,142,000 |
| Amortization Of Securities | $-7,501,000 | $-12,241,000 | $-3,071,000 | $0 |
| Depreciation Amortization Depletion | $1,418,000 | $189,000 | $0 | - |
| Depreciation And Amortization | $1,418,000 | $189,000 | $0 | - |
| Depreciation | $1,418,000 | $189,000 | $0 | - |
| Net Income From Continuing Operations | $-255,843,000 | $-182,146,000 | $-83,985,000 | $-39,785,000 |
Fetched: 2026-06-03